Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders.
Location: United States, Massachusetts, Boston
Member count: 11-50
Total raised: $215M
Founded date: 2005
Investors 2
| Date | Name | Website |
| - | Alta Partn... | altapartne... |
| - | RA Capital... | racap.com |
Funding Rounds 5
| Date | Series | Amount | Investors | Deal News |
| 20.06.2014 | IPO | $96M | - | medcitynew... |
| 17.04.2014 | - | $20M | - | finsmes.co... |
| 04.12.2013 | Series E | $45M | - | vcnewsdail... |
| 04.12.2012 | Series D | $21M | - | vcnewsdail... |
| 07.07.2011 | Series C | $33M | - | finsmes.co... |
Mentions in press and media 24
| Date | Title | Description | Category | Author | Source |
| 13.06.2019 | Zafgen pre... | The drug is a MetAP2 inhibitor... | - | - | medcitynew... |
| 31.10.2016 | Third Rock... | Fund IV has not yet begun inve... | - | - | medcitynew... |
| 19.07.2016 | Beleague... | Stymied at the FDA with a lin... | - | John Carro... | endpts.com... |
| 29.06.2016 | The biotec... | There was a time after the 20... | Financing | John Carro... | endpts.com... |
| 02.04.2015 | ZappRX rai... | ZappRx will also work with obe... | - | - | medcitynew... |
| 19.06.2014 | IPO for ob... | Instead of suppressing hunger,... | - | - | medcitynew... |
| 17.04.2014 | Zafgen Clo... | Zafgen, Inc., a Cambridge, MA-... | funding U... | - | finsmes.co... |
| 04.12.2013 | Zafgen Sec... | Zafgen, Inc., a Cambridge, MA-... | funding U... | - | finsmes.co... |
| 04.12.2013 | Zafgen lan... | Zafgen CEO Tom Hughes told Fie... | Venture Ca... | - | fiercebiot... |
| 04.12.2013 | Zafgen Sec... | CAMBRIDGE, MA, Leading bioph... | - | - | vcnewsdail... |
Show more